TCRs against tumor‐specific antigens are typically screened from TILs or peripheral blood mononuclear cells (PBMCs) and then introduced into T cells via retroviral transduction.[9] Lately, the US FDA approved afami‐cel, targeting HLA‐A*02‐MAGE‐A4, for the treatment of unresectable or metastatic synovial sarcoma.[10] Like CAR‐T therapy, TCR‐T therapy also faces challenges such as CRS and OTOT toxicities, and cross‐reactivity may occur when cross‐reactive epitopes in normal tissues are present.[11]. The gene discussed is MAGEA4; the disease is neoplasm.